Wells Fargo’s Forte Biosciences FBRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $13K | Hold |
502
| – | – | ﹤0.01% | 5906 |
|
|
2025
Q4 | $13.7K | Buy |
502
+500
| +25,000% | +$8.77K | ﹤0.01% | 5884 |
|
|
2025
Q3 | $30 | Hold |
2
| – | – | ﹤0.01% | 6602 |
|
|
2025
Q2 | $26 | Buy |
+2
| New | +$17 | ﹤0.01% | 6722 |
|
|
2024
Q2 | – | Sell |
-10
| Closed | -$176 | – | 7072 |
|
|
2024
Q1 | $176 | Hold |
10
| – | – | ﹤0.01% | 6522 |
|
|
2023
Q4 | $204 | Buy |
10
+1
| +11% | +$14 | ﹤0.01% | 6603 |
|
|
2023
Q3 | $156 | Buy |
9
+3
| +50% | +$66 | ﹤0.01% | 6642 |
|
|
2023
Q2 | $144 | Buy |
6
+1
| +20% | +$26 | ﹤0.01% | 6788 |
|
|
2023
Q1 | $133 | Hold |
5
| – | – | ﹤0.01% | 6874 |
|
|
2022
Q4 | $126 | Buy |
5
+1
| +25% | +$26 | ﹤0.01% | 6741 |
|
|
2022
Q3 | $0 | Buy |
4
+1
| +33% | +$32 | ﹤0.01% | 6842 |
|
|
2022
Q2 | $0 | Sell |
3
-1,700
| -100% | -$54K | ﹤0.01% | 6989 |
|
|
2022
Q1 | $62K | Buy |
1,703
+1,412
| +485% | +$53.4K | ﹤0.01% | 5548 |
|
|
2021
Q4 | $16K | Sell |
291
-208
| -42% | -$14K | ﹤0.01% | 6396 |
|
|
2021
Q3 | $36K | Sell |
499
-236
| -32% | -$131K | ﹤0.01% | 5744 |
|
|
2021
Q2 | $619K | Buy |
735
+732
| +24,400% | +$660K | ﹤0.01% | 4507 |
|
|
2021
Q1 | $2K | Sell |
3
-250
| -99% | -$205K | ﹤0.01% | 6634 |
|
|
2020
Q4 | $230K | Buy |
253
+251
| +12,550% | +$236K | ﹤0.01% | 5008 |
|
|
2020
Q3 | $3K | Buy |
2
+1
| +100% | +$663 | ﹤0.01% | 6084 |
|
|
2020
Q2 | $0 | Sell |
1
-93
| -99% | -$41.6K | ﹤0.01% | 6422 |
|
|
2020
Q1 | $43K | Buy |
94
+20
| +27% | +$7.82K | ﹤0.01% | 5389 |
|
|
2019
Q4 | $15K | Sell |
74
-14
| -16% | -$3.17K | ﹤0.01% | 5800 |
|
|
2019
Q3 | $22K | Sell |
88
-55
| -38% | -$83.5K | ﹤0.01% | 5786 |
|
|
2019
Q2 | $359K | Buy |
143
+54
| +61% | +$160K | ﹤0.01% | 4612 |
|
|
2019
Q1 | $364K | Buy |
89
+5
| +6% | +$19.3K | ﹤0.01% | 4519 |
|
|
2018
Q4 | $259K | Buy |
84
+1
| +1% | +$4.31K | ﹤0.01% | 4764 |
|
|
2018
Q3 | $488K | Buy |
83
+1
| +1% | +$3.81K | ﹤0.01% | 4461 |
|
|
2018
Q2 | $288K | Sell |
82
-13
| -14% | -$47.6K | ﹤0.01% | 4831 |
|
|
2018
Q1 | $422K | Buy |
95
+10
| +12% | +$46.3K | ﹤0.01% | 4522 |
|
|
2017
Q4 | $325K | Buy |
85
+43
| +102% | +$172K | ﹤0.01% | 4698 |
|
|
2017
Q3 | $197K | Buy |
42
+1
| +2% | +$4.46K | ﹤0.01% | 4935 |
|
|
2017
Q2 | $183K | Buy |
+41
| New | +$231K | ﹤0.01% | 4839 |
|
Other funds holding FBRX
FAM
O
AAA
MB
VCM
CCC
Wells Fargo's FBRX Position: Q1 2026 in Review
Wells Fargo held its Forte Biosciences (FBRX) position steady in Q1 2026 at 502 shares worth $13K. The position accounts for ﹤0.01% of the portfolio, ranked #5906.
Wells Fargo first reported a position in FBRX in Q2 2017 and has held it in 32 quarters since. The position peaked at $619K in Q2 2021. 68 funds tracked by Wall St. Rank hold FBRX as of Q1 2026.
- Wells Fargo held 502 shares of Forte Biosciences worth $13K as of Q1 2026.
- Wells Fargo left its Forte Biosciences share count unchanged in Q1 2026.
- Forte Biosciences made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #5906 holding.
- Wells Fargo first reported a position in Forte Biosciences in Q2 2017 and has held it in 32 quarters since.
- Wells Fargo's Forte Biosciences position peaked at $619K in Q2 2021.
- 68 funds tracked by Wall St. Rank held Forte Biosciences as of Q1 2026.
Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.